Perspective on the risks of infection and malignancy with rheumatoid arthritis therapy

Future Rheumatology

Volumn 3, Issue 5, 2008, Pages 445-449

  Hudson, Marie ^a   Suissa, Samy ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Epidemiology; Malignancy; Rheumatoid arthritis; Serious infections; Study design; Tumor necrosis factor antagonists

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR;

ANKYLOSING SPONDYLITIS; ARTICLE; AUTOIMMUNE DISEASE; BIOLOGICAL THERAPY; CANCER RISK; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; CLINICAL TRIAL; HEART PROTECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INFECTION SENSITIVITY; LUNG CANCER; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; SKIN CANCER; TREATMENT DURATION; TUBERCULOSIS;

EID: 70350589628     PISSN: 17460816     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460816.3.5.445     Document Type: Article

References (26)

1. Chakravarty EF, Genovese MC: Associations between rheumatoid arthritis and malignancy. Rheum. Dis. Clin. North. Am. 30(2), 271-284, vi (2004).
2. Smitten AL, Simon TA, Hochberg MC, Suissa S: A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res. Ther. 10(2), R45 (2008).
3. Michaud K, Wolfe F: Comorbidities in rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 21(5), 885-906 (2007).
4. Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L: Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 317(7152), 180-181 (1998).
5. Radis CD, Kahl LE, Baker GL et al.: Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20 year follow-up study. Arthritis Rheum. 38(8), 1120-1127 (1995).
6. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295(19), 2275-2285 (2006).
7. Costenbader KH, Glass R, Cui J, Shadick N: Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. JAMA 296(18), 2201; author reply 3-4 (2006).
8. Fleischmann R, Baumgartner SW, Weisman MH, Liu T, White B, Peloso P: Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann. Rheum. Dis. 65(3), 379-384 (2006).
9. Okada SK, Siegel JN: Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. JAMA 296(18), 2201-2202; author reply 3-4 (2006).
10. Geborek P, Bladstrom A, Turesson C et al.: Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann. Rheum. Dis. 64(5), 699-703 (2005).
11. Wolfe F, Michaud K: Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. 56(9), 2886-2895 (2007).
12. Wolfe F, Michaud K: The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 56(5), 1433-1439 (2007).
13. Askling J, Fored CM, Baecklund E et al.: Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann. Rheum. Dis. 64(10), 1414-1420 (2005).
14. Askling J, Fored CM, Brandt L et al.: Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann. Rheum. Dis. 64(10), 1421-1426 (2005).
15. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE: Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 46(9), 2287-2293 (2002).
16. Franklin J, Lunt M, Bunn D, Symmons D, Silman A: Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann. Rheum. Dis. 66(3), 308-312 (2007).
17. Bongartz T, Matteson EL, Orenstein R: Tumor necrosis factor antagonists and infections: the small print on the price tag. Arthritis Rheum. 53(5), 631-635 (2005).
18. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP: Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 54(8), 2368-2376 (2006).
19. Curtis JR, Patkar N, Xie A et al.: Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 56(4), 1125-1133 (2007).
20. Askling J, Fored C, Brandt L: Time-dependent increase in risk of hospitalisation with infection among swedish RA patients treated with TNF antagonists. Ann. Rheum. Dis. 66, 1339-1344 (2007).
21. Askling J, Dixon W: The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr. Opin. Rheumatol. 20, 138-14 (2008).
22. Smitten AL, Choi HK, Hochberg MC et al.: The risk of hospitalized infection in patients with rheumatoid arthritis. J. Rheumatol. 35(3), 387-393 (2008).
23. Winthrop KL: Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat. Clin. Pract. Rheumatol. 2(11), 602-610 (2006).
24. Wolfe F, Michaud K, Anderson J, Urbansky K: Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 50(2), 372-379 (2004).
25. Jacobsson LT, Turesson C, Gulfe A et al.: Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol. 32(7), 1213-1218 (2005).
26. Suissa S, Bernatsky S, Hudson M: Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum. 55(4), 531-536 (2006).